OKYO PHARMA LIMITED
$1.07 -0.0200 +0.94% 15.2K
Company Overview
OKYO Pharma a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy. Leveraging a unique lipid-conjugated chemerin peptide, OKYO’s lead candidate, OK-101, is designed to address inflammation and pain more effectively than current treatments. The recent Phase 2 trial for DED demonstrated notable improvements in both symptoms and signs within just 15 days, with a favorable safety profile and no drug-related serious adverse events. Moreover, OK-101 also offers a significant opportunity to treat the ocular disease called NCP, with no FDA approved drug to treat patients suffering from this acute, chronic, ocular condition. OKYO’s robust patent protection through at least 2039, plus an experienced management team, with proven success in clinical development thru FDA approval, underscore its strong positioning for future growth in ophthalmology therapeutics.
Value Proposition
OKYO is advancing its lead candidate, OK-101, a novel lipid-conjugated chemerin peptide, which targets both Dry Eye Disease (DED) and Neuropathic Corneal Pain (NCP), two significant areas of unmet medical need.
The recent Phase 2 trial for DED demonstrated rapid and notable improvements in symptoms and signs within just 15 days, coupled with a strong safety profile and no drug-related serious adverse events. With over 38 million people affected by DED in the U.S. alone, OK-101 could capture a substantial share of this multi-billion-dollar market upon approval. Additionally, the potential to address NCP, a condition with no FDA-approved therapies, opens a new market opportunity with significant growth potential. OKYO’s robust intellectual property portfolio, which extends through at least 2039, further strengthens its competitive advantage.
The company is led by an experienced management team, with CEO Dr. Gary S. Jacob, who has over 35 years in the biopharma industry and has successfully guided a drug through FDA approval, and CSO Dr. Raj Patil, who brings 30 years of ophthalmic research expertise. Looking ahead, OKYO plans to initiate a Phase 2 trial for NCP in Q3 2024, providing multiple near-term catalysts for investors. This combination of a differentiated product candidate, significant market opportunities, and experienced leadership makes OKYO Pharma a compelling investment opportunity in the ophthalmology therapeutics space.
Investor Presentation
Investment Highlights
Innovative pipeline targeting large, underserved markets with high unmet medical needs
- Lead candidate, OK-101, a novel lipid-conjugated chemerin peptide, targets two significant ocular conditions: Dry Eye Disease (DED) and Neuropathic Corneal Pain (NCP)
- DED is a multi-billion-dollar market with over 38 million affected individuals in the U.S. alone
- NCP represents an untapped market with no current FDA-approved treatments, offering substantial growth potential for OKYO
- Recent Phase 2 trial for OK-101 in DED showed significant improvements in both symptoms and signs as early as 15 days, with a strong safety profile and no drug-related serious adverse events
- Expect to launch Phase 2 trial for NCP in 3Q24
Strong intellectual property
- Patents provide protections through at least 2039 with potential extensions further enhancing competitive position
Experienced leadership with proven track record
- Extensive experience in drug development with history of successful drug commercialization
- CEO co-founded Synergy Pharmaceuticals and was instrumental in developing and securing FDA approval for Trulance®, a drug now marketed by Bausch Health
- CSO brings 30+ years of ophthalmic research and pharmaceutical R&D experience; authored 50+ peer-reviewed publications
Sign Up For OKYO Email News Alerts
Disclosure
RedChip Companies, Inc. research reports, company profiles, and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that RedChip Companies Inc. is an investor relations firm hired by certain companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles, or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the Ontario Securities Commission (“OSC”) at www.osc.gov.on.ca.
OKYO Pharma (OKYO) is a client of RedChip Companies, Inc. OKYO agreed to pay RedChip Companies, Inc. a $10,000 monthly cash fee, beginning in August 2024, and 50,000 stock options with a $1 strike price and five-year expiration, for six month of investor awareness services. RedChip intends to and will, if possible, exercise and sell all of its options immediately upon eligibility, and you may be buying as RedChip is selling. OKYO also agreed to pay RedChip a one-time forty-four thousand dollar fee for a 10-day national TV ad campaign aired June 11 through June 25, 2024, a one-time twenty-thousand dollar fee for a five-day national TV ad campaign aired August 5 through August 9, 2024, a one-time thirty-eight-thousand five-hundred dollar fee for a 10-day national TV ad campaign aired October 16 through October 29, 2024, and a one-time #33,000 cash fee for a 10-day national TV ad campaign aired November 7 through November 20, 2024.
Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.